5054
SallY A. A' Abou Taleb
,, Innovation of a1 Ini ectabl e'sustained Release I rnsiru-F1?l'i; for Fluoxetine
Fluoxetine hydrochloride / 'sustained Release / Ini ectable
Fluoxetine hydrochloride (fluoxetine HCD is a novel ar-rtidepr-essant dmg. It is widely used in var-ious types of psychiatric disorders like major depression, bipolar depression and obsessive compulsive disorders' Fluoxetine HCl is a selective serotonin reuptake inhibitor and possesses weak affrnity for muscarinic receptors and therefore exhibits lesser antic[olinergic side effects than that caused by other traditional antidepressants like hicyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOIs). Dose of fluoxetine HCl ranges fi'om 20-80 mg administered as one to four capsules a day. This dose and frequency may cause enhanced dmg related side effects and may pose compliance problems. lt has also been reported that fluoxetine HCl undergoes hepatic first pass metabolism. Among the common adverse effects associated with fluoxetine and listed in the prescribing information, the effects with the greatest difference from placebo are nausea, insomnia, sqmnolence,anorexia, anxiety, nervousness, asthenia and tremor.
2015
Ph.d
Cairo
Pharmacy